Europital launches as a science-driven full-service CRO
Expanded CRO services to support biotechs and mid-sized pharma companies across trials in more than 40 countries.
Europital, a globally focused full-service CRO serving small and mid-tier innovators, has launched new capabilities across project management, clinical monitoring, biostatistics, pharmacovigilance, regulatory affairs and data management, in addition to its existing medical affairs and medical writing services.
The expanded clinical research offering will see Europital support clients in more than 40 countries from investigational new drug (IND) through to commercial launch.
Dr Mohamed El Malt, Chief Medical Officer of Europita, said: “It’s no secret, there is a large gap in the CRO industry for these small innovators; what they need is a science-driven CRO that will support them closely with an experienced senior team but combined with a global trial network."
Europital has regional offices in Belgium, Hungary and the UK, with customers based in Europe and the US. Innovators developing therapies for oncology, infectious diseases, inflammatory and autoimmune diseases will be the major beneficiaries of the company's multifunctional and operational capabilities.
Sponsors who will particularly benefit are those that require a full range of CRO services for complex molecules and trial designs that necessitate senior medical and scientific oversight.
In addition to its regional offices in Europe, Europital has built a global network of trusted partners during the last 10 years with local operational expertise and preferential supply trial site agreements in the US, Canada, Russia, India, the Middle East and North Africa and Australia.
Dr El Malt explained that the decision to launch as a full-service CRO reflects the many requests it received from its clients to work on additional aspects of their clinical trials, the services for which they did not have in-house. Now, with the expansion, the company can provide a 360-degree CRO service to innovators in the pharmaceutical, biotechnology and medical devices sectors.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance